Description

The year 2018 was a breakthrough period for RNA therapeutics as the first RNA therapy received approval from the FDA. In the wake of the COVID-19 pandemic, RNA vaccines have witnessed immense progress and acceptance globally. These events have contributed massively to growth across the RNA therapeutics market.

Currently, several RNA therapeutics are in different stages of development, including mRNA, tRNA, siRNA, and RNAi therapies, but mostly concentrated in the early pre-clinical and clinical stages. The popularity of RNA therapeutics is demanding the need to establish efficient delivery systems that can overcome current challenges, such as early degradation of RNA therapeutic molecules, toxicity, and non-target specificity.

This RNA Delivery Technologies, 2021 Frost Radar™ covers companies that are developing robust delivery systems for the rapidly growing RNA therapies and adopting the latest advances in nanoscience and chemically modified delivery systems. These delivery systems are critical to achieving the final results in the efficiency of RNA therapeutics.

Frost & Sullivan identifies key companies that are developing innovative RNA delivery technologies and excelling in the field. Although the newer delivery systems are mostly in pre-clinical stages, the potential of newer delivery systems based on exosomes, chemically modified systems, and polymer-based systems are highly promising.

Frost & Sullivan independently plotted the top companies in this Frost Radar™. Our analysis reveals the market positioning of each company using its Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies based on their strengths, opportunities, and market positioning. We discuss strategic market imperatives and the competitive environment that vendors operate in as well as make recommendations for each provider to spur growth.